British biotech developing mitochondria-targeted therapies for ALS and Parkinson's.
| Date | Round | Amount |
|---|---|---|
| Sep 2025 | Series B NRG Therapeutics raised £50 million in a Series B led by SV Health's Dementia Discovery Fund to bring its mitochondrial candidate NRG5051 into the clinic. | $63.5M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.